Fig. 7: PVTX-405 in combination with either Anti-PD1 or Anti-LAG3 shows synergistic anti-cancer efficacy in the MC38 mouse tumor xenograft model in immune competent Crbn^I391V C57BL/6 mice.

a Kaplan-Meier survival curve for time it requires animal to reach tumor volume of 2000 mm³. PVTX-405 induces significantly better tumor growth reduction in combination with PD1 blockade as compared to PD1 blockade alone (p = 0.029, log-rank test, two sided). b Spider plot showing tumor growth kinetics for each animal in various treatment groups for the duration of the study. PVTX-405 shows more complete responses in combination with anti-PD1 than anti-PD1 alone. c Kaplan-Meier survival curve for time it requires animal to reach tumor volume of 2000 mm³. PVTX-405 induced significantly better tumor growth reduction in combination with LAG3 blockade compared to LAG3 alone (p = 0.025, log-rank test, two sided). d Spider plot showing tumor growth kinetics for each animal in various treatment groups for the duration of the study. PVTX-405 shows a significant increase in complete responses in combination with anti-LAG3 than anti-LAG3 alone. e Animal body weight change for the group of PVTX-405 + Anti-PD1 combination study. Data presented as mean ± SD, with n = 10 animals for each treatment group. f Animal body weight change for the group of PVTX-405 + Anti-LAG3 combination study. Data presented as mean ± SD, with n = 10 animals for each treatment group. Source data are provided as a Source Data file.